Related Experiment Video

Updated: Nov 24, 2025

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

137

Commentary: Find, resect, and treat: The evolving early-stage small cell lung cancer story

Scott J Swanson1

  • 1Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass.

The Journal of Thoracic and Cardiovascular Surgery
|December 23, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.9K

Related Experiment Videos

Last Updated: Nov 24, 2025

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

137
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Cumulative high-risk surgical and pathologic features predict recurrence after resection of early-stage node-negative non-small cell lung cancer.

JTCVS open·2026

Long-term survival for preoperative versus postoperative treatment of N2 lung cancer: The importance of complete adjuvant therapy for occult N2 disease.

JTCVS open·2025

Real-time margin assessment for video-assisted thoracic surgery: A pilot clinical trial.

JTCVS techniques·2025

Delayed Esophagectomy After Chemoradiation Is Not Associated With Increased Mortality or Recurrence.

Journal of surgical oncology·2025

Segmentectomy vs Lobectomy for Occult N1 in Non-Small Cell Lung Cancer: Is Less More?

The Annals of thoracic surgery·2025

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.

The New England journal of medicine·2025

Transcatheter Valve-in-Valve versus Surgical Aortic Valve Replacement for Failed Bioprostheses: AI-ECG Age as a Marker of Mortality.

The Journal of thoracic and cardiovascular surgery·2026

Coronary Artery Aneurysms: Evolving Trends in Surgical Management.

The Journal of thoracic and cardiovascular surgery·2026

2026 Revised Recommendations of The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2026

Modified Right Vertical Infra-Axillary Thoracotomy for Ventricular Septal Defect Repair Across Age Groups: A Single-Center Cohort Study.

The Journal of thoracic and cardiovascular surgery·2026

Neoadjuvant Chemoradiotherapy Versus Perioperative Chemotherapy ± Immunotherapy in Resectable Esophageal Adenocarcinoma.

The Journal of thoracic and cardiovascular surgery·2026

Minimally invasive cardiac surgery for tetralogy of Fallot: early outcomes from a single-center experience.

The Journal of thoracic and cardiovascular surgery·2026

The effects of combined aerobic and resistance exercise on metabolic blood biomarkers and quality of life in patients with breast cancer: a systematic review meta-analysis.

Frontiers in oncology·2026

New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy.

Frontiers in allergy·2026

Case Report: Can this 90-year-old patient with cT4N3M0 NSCLC have concurrent chemoradiation for cure? Learning from a representive case.

Frontiers in oncology·2026

Conjunctival reactive cutaneous capillary endothelial proliferation induced by camrelizumab in an esophageal cancer patient: a case report and literature review.

Frontiers in oncology·2026

Oxygen-Gradient-Responsive Photosensitizing Gadolinium Phthalocyaninate for Self-Adaptive Type II/I Photodynamic Therapy Toward Heterogeneous Tumor Suppression.

Small (Weinheim an der Bergstrasse, Germany)·2026

An Immunogenic Cell Death-Enhanced Self-Assembled Nanoparticle-Composite Hydrogel for Postoperative Local Immunotherapy of Melanoma.

Omics : a journal of integrative biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us